|
Market Closed -
Other stock markets
|
Pre-market 08:13:35 am | |||
| 203.87 USD | -2.20% |
|
202.72 | -0.57% |
| 02:48am | Citi Downgrades ResMed to Neutral From Buy; Price Target is AU$34 | MT |
| Jul. 10 | Jefferies Adjusts Price Target on ResMed to $225 From $240 | MT |
Main competitors
| 1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Visibility | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|
| 15 | ||||||||
| 26 | ||||||||
| 30 | ||||||||
| 23 | ||||||||
| 29 | ||||||||
| 26 | ||||||||
| 20 | ||||||||
| 19 | ||||||||
| 24 | ||||||||
| 19 | ||||||||
| 19 | ||||||||
| 20 | ||||||||
| 18 | ||||||||
| 15 | ||||||||
| 13 | ||||||||
| 12 | ||||||||
| 3 | ||||||||
| 6 | ||||||||
| 9 | ||||||||
| Average | 18 | |||||||
| Weighted average by Cap. | 24 |
- Stock Market
- Stocks
- RMD Stock
- Sector ResMed, Inc.
- Sector revisions
Select your edition
All financial news and data tailored to specific country editions
















